ClinVar Miner

Submissions for variant NM_003661.3(APOL1):c.[1024A>G;1152T>G]

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV001195215 SCV001365522 risk factor Hyalinosis, Segmental Glomerular 2020-03-04 criteria provided, single submitter clinical testing APOL1 c.[1024A>G;1152T>G] (p.[Ser342Gly;Ile384Met]), traditionally referred to as G1, has been associated with increased risk for multiple renal diseases in African Americans, particularly focal segmental glomerulosclerosis (FSGS), as well as an increased risk for end-stage kidney disease (ESKD). This variant is common in individuals of African ancestry (23%, Genome Aggregation Database (gnomAD); rs73885319 and rs60910145) and is present in ClinVar (ID: 6080). Several small case-control studies have reported odds ratios between 9.66-47.4 for developing FSGS/HIVAN in homozygous individuals (OR=47.4 [95% CI 11.9-231.5] for HIVAN and OR=23.2 [95% CI 12-46.7] for FSGS Kopp 2011, OR=9.66 [95% CI not given, P<0.00001] Limou 2015). In vitro and in vivo studies provide evidence that these alleles impact protein function (Beckerman 2017, Hayek 2017). In summary, this variant is an established risk factor for chronic kidney disease in homozygous state.
OMIM RCV000006453 SCV000026636 risk factor Focal segmental glomerulosclerosis 4, susceptibility to 2010-08-13 no assertion criteria provided literature only
Department of Pathology and Laboratory Medicine, Sinai Health System RCV002468554 SCV002764632 established risk allele Focal segmental glomerulosclerosis, susceptibility to no assertion criteria provided research The APOL1 c.[1024A>G;1152T>G]; p.[Ser342Gly;Ile384Met] (ALIAS: c.[1072A>G; 1200T>G]; p.[Ser358Gly; Ile400Met]) variant, otherwise known as the G1 allele/haplotype, has been associated with increased risk for multiple renal diseases in African Americans, particularly focal segmental glomerulosclerosis (FSGS), as well as an increased risk for end-stage kidney disease (ESKD). This variant is common in individuals of African ancestry (23%, Genome Aggregation Database (gnomAD); rs73885319 and rs60910145) and is present in ClinVar (ID: 6080). Several small case-control studies have reported odds ratios (ORs) between 9.66-47.4 for developing FSGS/HIV-associated nephropathy (HIVAN) in homozygous individuals (OR=47.4 [95% CI 11.9-231.5] for HIVAN and OR=23.2 [95% CI 12-46.7] for FSGS (Kopp_2011_21997394), OR=9.66 [95% CI not given, P<0.00001] (Limou_2015_25993319)). In a recessive model, individuals carrying any combination of two APOL1 risk alleles had 89-fold higher odds (95% confidence interval, 18 to 912; P<0.001) of developing HIV-associated nephropathy compared with HIV-positive controls (Kasembeli_2015_25788523). More evidence is available in the literature demonstrating an increased odds ratio of various (but not all) kidney and glomerular diseases in persons carrying two of the risk alleles, i.e. G1/G1, G2/G2 and compound heterozygous G1/G2 (PMID: 25100047, 25788523, 21997394, 23766536, 24504811, 23520206, 24731740, 32561682, 33576823, 34352311, 34670811). Mechanistically, the G1 and G2 variants appear to act as gain-of-function, increasing APOL1 channel activity (PMID: 33380423, 32427098) and APOL1-mediated cytotoxicity (PMID: 26091559, 26699492, 32427098, 24899058, 26089538). In vitro and in vivo studies provide evidence that these alleles impact protein function (Beckerman 2017, Hayek 2017). In summary, the presence of two copies of the APOL1 risk variants G1 and/or G2 (ClinVar Variation IDs: 6080 and 6081) is definitively associated with an increased susceptibility to multiple glomerular and hypertensive kidney diseases, most prominently FSGS and HIVAN (OMIM:612551). The preferred disease name suggested for this grouping of disorders is ‘Glomerulopathy, susceptibility - APOL1’. (Adapted from: Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine; Accession: SCV001365522.1 AND ClinGen: APOL1 - focal segmental glomerulosclerosis 4, susceptibility to). In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant meets our laboratory's criteria to be classified as a likely pathogenic - risk factor in association with susceptibility to focal segmental glomerulosclerosis when present in the homozygous or compound heterozygous (with G2 allele) state.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.